The PE Ratio as of July 2024 (TTM) for DICE Therapeutics, Inc. (DICE) is -21.91

According to DICE Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -21.91. This represents a change of 50.78% compared to the average of -14.53 of the last 4 quarters.

DICE Therapeutics, Inc. (DICE) Historical PE Ratio (quarterly & annually)

How has DICE PE Ratio performed in the past?

The mean historical PE Ratio of DICE Therapeutics, Inc. over the last ten years is -30.92. The current -21.91 PE Ratio has changed 6.99% with respect to the historical average. Over the past ten years (40 quarters), DICE's PE Ratio was at its highest in in the December 2020 quarter at 0. The PE Ratio was at its lowest in in the June 2021 quarter at -42.98.

DICE Therapeutics, Inc. (DICE) PE Ratio by Quarter and Year

Discovering the peaks and valleys of DICE Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

DICE Therapeutics, Inc. (DICE) Average PE Ratio

How has DICE PE Ratio performed in the past?

The current PE Ratio of DICE Therapeutics, Inc. (DICE) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

DICE Therapeutics, Inc. (DICE) PE Ratio vs. Peers

How is DICE’s PE Ratio compared to its peers?

DICE Therapeutics, Inc.’s PE Ratio is greater than Nuvalent, Inc. (-35.98), greater than Arcellx, Inc. (-67.23), less than Vaxcyte, Inc. (-21.49), less than Viridian Therapeutics, Inc. (-4.67), less than Ventyx Biosciences, Inc. (-0.95), greater than Immunocore Holdings plc (-24.67), less than Cytokinetics, Incorporated (-11.47), less than Edgewise Therapeutics, Inc. (-15.70), greater than Karuna Therapeutics, Inc. (-29.52), less than Dyne Therapeutics, Inc. (-14.02), less than Chinook Therapeutics, Inc. (-11.89), less than Pliant Therapeutics, Inc. (-4.71), less than Crinetics Pharmaceuticals, Inc. (-16.69), less than Ascendis Pharma A/S (-13.97), less than Terns Pharmaceuticals, Inc. (-7.36), less than Day One Biopharmaceuticals, Inc. (-6.65), less than Acumen Pharmaceuticals, Inc. (-3.72), less than Amylyx Pharmaceuticals, Inc. (-1.88), greater than MoonLake Immunotherapeutics (-68.94),

Build a custom stock screener for DICE Therapeutics, Inc. (DICE) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like DICE Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

DICE Therapeutics, Inc. (DICE) and other stocks custom spreadsheet templates

The easiest way to analyze a company like DICE Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.